Quince Therapeutics 관리

관리 기준 확인 2/4

Quince Therapeutics CEO는 Dirk Thye, May2022 에 임명되었습니다 의 임기는 2.5 년입니다. 총 연간 보상은 $ 1.33M, 41.3% 로 구성됩니다. 41.3% 급여 및 58.7% 보너스(회사 주식 및 옵션 포함). 는 $ 1.76M 가치에 해당하는 회사 주식의 1.92% 직접 소유합니다. 1.76M. 경영진과 이사회의 평균 재임 기간은 각각 1.5 년과 5.7 년입니다.

주요 정보

Dirk Thye

최고 경영자

US$1.3m

총 보상

CEO 급여 비율	41.3%
CEO 임기	2.5yrs
CEO 소유권	1.9%
경영진 평균 재임 기간	1.5yrs
이사회 평균 재임 기간	5.7yrs

최근 관리 업데이트

Recent updates

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

Aug 20

Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation

Nov 21

Insider Buying: The Cortexyme, Inc. (NASDAQ:CRTX) Independent Director Just Bought 2.4% More Shares

Mar 10

CEO 보상 분석

Dirk Thye 의 보수는 Quince Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$53m
Jun 30 2024	n/a	n/a	-US$53m
Mar 31 2024	n/a	n/a	-US$30m
Dec 31 2023	US$1m	US$550k	-US$31m
Sep 30 2023	n/a	n/a	-US$28m
Jun 30 2023	n/a	n/a	-US$31m
Mar 31 2023	n/a	n/a	-US$42m
Dec 31 2022	US$5m	US$317k	-US$52m

보상 대 시장: Dirk 의 총 보상 ($USD 1.33M )은 US 시장( $USD 650.80K ).

보상과 수익: Dirk 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Dirk Thye (54 yo)

2.5yrs

테뉴어

US$1,330,500

보상

Dr. Dirk Thye, M.D., served as Chief Executive Officer, President and Director at Novosteo Inc. He has been Director at Kainomyx, Inc. Dr. Thye serves as Chief Medical Officer of Quince Therapeutics, Inc....

리더십 팀

이름	위치	테뉴어	보상	소유권
Dirk Thye	CEO, Chief Medical Officer & Director	2.5yrs	US$1.33m	1.92% $ 1.8m
Charles Ryan	President	1.2yrs	US$1.11m	0.28% $ 254.7k
Brendan Hannah	Chief Business Officer	1.7yrs	US$847.50k	0.67% $ 616.8k
Giovanni Mambrini	Chief Technology Officer	1.1yrs	데이터 없음	데이터 없음
Guenter Janhofer	Chief Scientific Officer	1.1yrs	데이터 없음	0.034% $ 31.2k
Stacy Roughan	Vice President of Corporate Communications & Investor Relations	3.8yrs	데이터 없음	데이터 없음
Mary Sillivos	Vice President of Human Resources	4.8yrs	데이터 없음	데이터 없음
Stewart Low	Head of Discovery	2.5yrs	데이터 없음	데이터 없음
Thomas Sabia	Chief Commercial Officer	1.1yrs	데이터 없음	데이터 없음
Pamela Williamson	Head of Regulatory Affairs	1.3yrs	데이터 없음	데이터 없음

1.5yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: QNCX 의 관리팀은 경험 (평균 재직 기간 1.5 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Dirk Thye	CEO, Chief Medical Officer & Director	2.5yrs	US$1.33m	1.92% $ 1.8m
Una Ryan	Lead Independent Director	5.8yrs	US$98.56k	0.0065% $ 6.0k
Ilan Zipkin	Member of Scientific Advisory Board	no data	US$44.84k	데이터 없음
Jeffrey Cummings	Member of Clinical Advisory Board	5.4yrs	데이터 없음	데이터 없음
Martin Farlow	Member of Clinical Advisory Board	no data	데이터 없음	데이터 없음
David Lamond	Independent Chairman of the board	8.9yrs	US$106.06k	9.96% $ 9.1m
Christopher Senner	Independent Director	5.7yrs	US$87.56k	0% $ 0
Margaret McLoughlin	Independent Director	8.9yrs	US$82.06k	0.018% $ 16.6k
Mark Brody	Member of Clinical Advisory Board	no data	데이터 없음	데이터 없음
David Munoz	Member of Clinical Advisory Board	no data	데이터 없음	데이터 없음
Mark Ryder	Member of Clinical Advisory Board	no data	데이터 없음	데이터 없음
Mauro Magnani	Chairman of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음

5.7yrs

평균 재임 기간

58.5yo

평균 연령

경험이 풍부한 이사회: QNCX 의 이사회는 경험(평균 재직 기간 5.7 년)으로 간주됩니다.

Quince Therapeutics 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

CEO, Chief Medical Officer & Director recently bought US$107k worth of stock

Quince Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

Quince Therapeutics, Inc. Launches Scientific Advisory Board

Quince Therapeutics, Inc. Appoints Rajiv Patni to Its Board of Directors

CEO & Director exercised options to buy US$336k worth of stock.

Independent Chairman of the board recently bought US$58k worth of stock

Recent updates

New minor risk - Shareholder dilution

Quince Therapeutics Presents Safety Data from Prior Phase 3 Attest Clinical Trial At 53rd Child Neurology Society Annual Meeting

New minor risk - Profitability

CEO, Chief Medical Officer & Director recently bought US$107k worth of stock

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

Quince Therapeutics, Inc. Announces the Online Publication of Data in the Lancet Neurology from Its Phase 3 Attest Clinical Trial Data Evaluating Erydex for the Treatment of Ataxia-Telangiectasia (A-T)

Quince Therapeutics, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2024

Quince Therapeutics Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Quince Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for EryDex System

Quince Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

Quince Therapeutics, Inc. Launches Scientific Advisory Board

Quince Therapeutics, Inc. Appoints Rajiv Patni to Its Board of Directors

CEO & Director exercised options to buy US$336k worth of stock.

Independent Chairman of the board recently bought US$58k worth of stock

Quince Therapeutics Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Quince Therapeutics, Inc. Appoints Brendan Hannah to the Position of Chief Operating Officer

Insufficient new directors

New minor risk - Shareholder dilution

Quince Therapeutics, Inc. Appoints Luca Benatti as Director

Quince Therapeutics, Inc. (NasdaqGS:QNCX) acquired EryDel S.p.A. for approximately $510 million.

Quince Therapeutics, Inc. Announces That U.S. Food and Drug Administration Lifts the Partial Clinical Hold on Erydel S.P. A's Investigational New Drug (Ind) Application for Its Lead Phase 3 Asset, Erydex

Quince Therapeutics Appoints Charles S. Ryan as President

Independent Chairman of the board recently bought US$108k worth of stock

Quince Therapeutics, Inc. Announces the Departure of Karen Smith as Chief Medical Officer, Effective September 1, 2023

CEO, President & Director recently bought US$99k worth of stock

New minor risk - Share price stability

Quince Therapeutics, Inc. (NasdaqGS:QNCX) agreed to acquire EryDel S.p.A. for approximately $490 million.

Biomed Industries, Inc. submitted a proposal to acquire Quince Therapeutics, Inc. (NasdaqGS:QNCX) for $10.5 million.

Price target increased by 56% to US$12.00

Quince Therapeutics Gets an Initial Compliance Period of 180 Calendar Days to Regain Compliance with the Minimum Bid Price Requirement

Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation

Insufficient new directors

Insufficient new directors

Quince Therapeutics, Inc. Presents Preclinical Data at OI 2022 Demonstrating Potential of a Targeted Anabolic for Accelerated Bone Healing of Osteogenesis Imperfecta Fractures

Price target increased to US$8.38

Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588

Cortexyme to change name and ticker symbol next month

Cortexyme, Inc. Announces Resignation of Leslie Holsinger as Executive Vice President of Research and Development, Effective July 31, 2022

Cortexyme, Inc.(NasdaqGS:CRTX) dropped from Russell 2000 Dynamic Index

Cortexyme, Inc. Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections

Cortexyme, Inc. Appoints June Bray to its Board of Directors

Cortexyme, Inc. Announces Resignation of Christopher Lowe as Chief Financial Officer

Cortexyme, Inc. (NasdaqGS:CRTX) acquired Novosteo Inc. from David Lamond and others for $19.8 million.

Dr. Dirk Thye and Philip Low to Join Cortexyme Board

Price target decreased to US$7.60

Cortexyme, Inc. Reports Safety and Pharmacokinetics Results from Single Ascending Dose Portion of Its Phase 1 Clinical Trial of Cor588

Price target decreased to US$7.60

Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment

Cortexyme, Inc. Announces Executives Changes

Cortexyme, Inc. Receives Letter from the U.S. Food and Drug Administration, Placing Full Clinical Hold on Atuzaginstat’s (COR388) Investigational New Drug Application

Price target increased to US$44.00

Cortexyme: Drug Candidate COR588 May Offer Some Hope To Investors

We're Keeping An Eye On Cortexyme's (NASDAQ:CRTX) Cash Burn Rate

COO, CFO & Treasurer exercised options to buy US$387k worth of stock.

Cortexyme: A Challenging Path Forward

Cortexyme: Positive Lessons To Be Learned From Disappointing Results

Cortexyme And The Gingipain Hypothesis Of Alzheimer's Disease

COO, CFO & Treasurer exercised options and sold US$217k worth of stock

Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease at CTAD 2021

Cortexyme: Alzheimer's Readout In November A Binary Event

Cortexyme, Inc. Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588

Price target increased to US$97.71

Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer’s Disease at Annual Biomarkers for Alzheimer’s Disease Summit

We Think Cortexyme (NASDAQ:CRTX) Can Afford To Drive Business Growth

Price target increased to US$89.00

Price target increased to US$78.29

Cortexyme, Inc. Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021

COO, CFO & Treasurer exercised options and sold US$1.0m worth of stock

Cortexyme, Inc.(NasdaqGS:CRTX) dropped from Russell 3000E Value Index